RP1

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Skin cancer, Immunotherapy, Risk, Patient, SAN, RP1, University, MD Anderson Cancer Center, Society, AACR, Carcinoma, CSCC, SITC, PD-L1, Skin, Pharmaceutical industry

The results were initially presented late last year at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Key Points: 
  • The results were initially presented late last year at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
  • In the evaluable patient population (n=23), 20 had cutaneous squamous cell carcinoma (CSCC) and three had merkel cell carcinoma.
  • Of note, a patient treated with RP1 for CSCC also had a complete response of a new primary basal cell carcinoma which appeared post baseline.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers.

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Retrieved on: 
Tuesday, March 26, 2024
Development, Growth, Skin cancer, Immunotherapy, Genentech, Philip, Patient, Lung, RP1, Skin, Cancer, Melanoma, Retirement, Marketing, BLA

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company’s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.

Key Points: 
  • Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024.
  • Mr. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors.
  • Dr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer.
  • Prior to joining Replimune, Dr. Patel served as franchise head for lung, skin and rare cancers at Genentech.

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 8, 2024
Carcinoma, Neoplasm, Melanoma, NMSC, Merkel-cell carcinoma, REPL, Angiosarcoma, SITC, PFS, Clinical trial, Research, RECIST, Society, Hercules, Patient, CSCC, Type, FDA, Marketing, Investment, RP1, Food, MCC, Immunotherapy, Skin, Nivolumab, Uveal melanoma, Annual general meeting, BLA, RP2, Pharmaceutical industry

WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.

Key Points: 
  • WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.
  • We plan to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024.
  • Selling, general and administrative expenses included $4.5 million in stock-based compensation expenses for the third quarter ended December 31, 2023.
  • Net Loss: Net loss was $51.1 million for the third quarter ended December 31, 2023, as compared to a net loss of $39.7 million for the third quarter ended December 31, 2022.

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Retrieved on: 
Tuesday, December 5, 2023
Chills, CRS, Melanoma, RP1, CRC, Food, Melanoma Research, RECIST, NMSC, Transplant, Diarrhea, FDA, Cytokine release syndrome, Colorectal cancer, SCCHN, Type, RP3, CRR, Fatigue, Headache, Nausea, Itch, Myocarditis, Incidence, Nivolumab, Influenza-like illness, Research, Clinical trial, Injection site reaction, Myalgia, CSCC, Skin cancer, HCC, Weakness, Society, Head, Appetite, RP2, Regeneron Pharmaceuticals, Carcinoma, Investment, Webcast, Patient, Lipase, Angiosarcoma, MCC, Vomiting, Neck, Uveal melanoma, Rash, BLA, Pharmaceutical industry

The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.

Key Points: 
  • The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
  • The ORR was comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692).
  • The registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients and completed enrollment earlier this year.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to that observed in non-immunocompromised patients with advanced skin cancers.

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Bevacizumab, Patient, FDA, Research, Carboplatin, RP1, NMSC, Biologics license application, Nivolumab, Biotechnology, Financial management, Carcinoma, Cisplatin, Data collection, Disclosure, SITC, Immunotherapy, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Initiation, RP3, Clinical trial, Marketing, Melanoma, Skin, Annual general meeting, RP2, PTC, CFO, Roche, Society, CSCC, PTC Therapeutics, Therapy, Investment, Calendar, BLA, D, Merkel-cell carcinoma, Pharmaceutical industry, Nursing, Cryptocurrency

WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • R&D Expenses: Research and development expenses were $49.1 million for the second quarter ended September 30, 2023, as compared to $28.8 million for the second quarter ended September 30, 2022.
  • S,G&A Expenses: Selling, general and administrative expenses were $14.7 million for the second quarter ended September 30, 2023, as compared to $12.7 million for the second quarter ended September 30, 2022.
  • Selling, general and administrative expenses included $4.7 million in stock-based compensation expenses for the second quarter ended September 30, 2023.
  • Net Loss: Net loss was $60.0 million for the second quarter ended September 30, 2023, as compared to a net loss of $43.1 million for the second quarter ended September 30, 2022.

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap

Retrieved on: 
Friday, November 3, 2023
RP1, Carcinoma, MD Anderson Cancer Center, MCC, Development, SITC, Immunotherapy, Skin, ORR, University, Society, CSCC, Patient, Skin cancer, Abstract, Transplant, Pharmaceutical industry

Treatment with RP1 monotherapy led to an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses).

Key Points: 
  • Treatment with RP1 monotherapy led to an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses).
  • One patient treated for CSCC also had a complete response of a new primary basal cell carcinoma which appeared post baseline that was treated with RP1.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers.
  • “Patients receiving organ transplants are highly susceptible to skin cancer at a rate which is far higher than in the general population.

Raspberry Pi 5 Single Board Computer, Now Orderable from Mouser, Delivers Significant Speed Improvements Over Previous Generations

Retrieved on: 
Monday, October 9, 2023
Electronic Design Automation, Engineering, Semiconductor, Consumer Electronics, Technology, Manufacturing, Hardware, GPU, Data-rate units, Multimedia, USB, Broadcom Inc., HDMI, Silicon, SD card, HDR, 2.0, RP1, PCI, Bluetooth Low Energy, UAS, Power, SCSI, Raspberry, Mouser, Dual, Robotics, CPU, PCI Express, Gigabit Ethernet, News, VideoCore, OpenGL, Electronics, SOC, Power over Ethernet, SBC, Video game, Ethernet

Building on the success of the Raspberry Pi 4, the Pi 5 single board computer (SBC) delivers a 2x – 3x increase in CPU performance, a significant uplift in GPU performance, and noticeable improvements to display, camera, and USB interfacing.

Key Points: 
  • Building on the success of the Raspberry Pi 4, the Pi 5 single board computer (SBC) delivers a 2x – 3x increase in CPU performance, a significant uplift in GPU performance, and noticeable improvements to display, camera, and USB interfacing.
  • View the full release here: https://www.businesswire.com/news/home/20231009177369/en/
    Now available to order from Mouser.com, the Raspberry Pi 5 is a game-changer with a few new tricks up its sleeve.
  • (Graphic: Business Wire)
    The Raspberry Pi 5 Single Board Computer, now available for order at Mouser, is the first full-size Raspberry Pi computer to be built with silicon developed in-house.
  • To learn more about the Raspberry Pi 5 Single Board Computer, visit https://www.mouser.com/new/raspberry-pi/raspberry-pi-5-sbc/ .

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023
Bevacizumab, Radiation, CRC, Skin, Roche, Clinical trial, Merkel-cell carcinoma, SCCHN, Data collection, Uveal melanoma, RP3, Incyte, SOC, Cisplatin, RP1, ASCO, ORR, CSCC, American Society of Clinical Oncology, Cytokine release syndrome, Patient, Standard of care, Melanoma, Carcinoma, CPS, Annual general meeting, Liver, Nivolumab, ATC, RP2, Kinetics, BLA, PD-L1, Society, Safety, Fatigue, Pharmaceutical industry, Vaccine, Medical imaging, Nursing

“It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.

Key Points: 
  • “It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.
  • S,G&A Expenses: Selling, general and administrative expenses were $15.2 million for the first quarter ended June 30, 2023, as compared to $11.4 million for the first quarter ended June 30, 2022.
  • Selling, general and administrative expenses included $5.5 million in stock-based compensation expenses for the first quarter ended June 30, 2023.
  • Net Loss: Net loss was $49.6 million for the first quarter ended June 30, 2023, as compared to a net loss of $42.3 million for the first quarter ended June 30, 2022.

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Monday, July 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Learning, Hematology, Clinical trial, Multimedia, RPX, RP1, Development, CSCC, Patient, Carcinoma, PD-L1, Safety, Pharmaceutical industry, Incyte

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.

Key Points: 
  • Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.
  • This press release features multimedia.
  • Under the terms of the agreement, Incyte will initiate and sponsor the clinical trial of INCB99280 and RP1 in patients with high risk, resectable cutaneous squamous cell carcinoma (CSCC), with the clinical trial expected to initiate in early 2024.
  • Replimune will supply Incyte with RP1 for the study and share equally in the costs of the study.

RP1 Shatters Metaverse Limits: Showcases Technology Platform Capable of Scaling to Billions of People

Retrieved on: 
Wednesday, June 14, 2023
Data Management, Technology, Software, Metaverse, Networks, Internet, Linda, Meta, AWE, Augmented World Expo, Web browser, Virtual, Central processing unit, PC, HTC, RP1, DATA, VR, CPU, Apple, Ecosystem, Imagination, AR, Tourism, Video game, Online shopping

RP1 offers the industry's first software solution to tackle this problem, unlocking the power of the largest hardware and chipset manufacturers.

Key Points: 
  • RP1 offers the industry's first software solution to tackle this problem, unlocking the power of the largest hardware and chipset manufacturers.
  • RP1 has paved the way for the Metaverse to become a reality today by building a new foundational standard on top of current Internet protocols.
  • On-Demand: No more App stores; on-demand content without the need for pre-installed downloads, accessible via web browser or native app.
  • “The Metaverse will be a new way for anyone to express themselves using tools as simple as TikTok and Instagram.